BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448
China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND)...
Drug
Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae
Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that...
Astellas Pharma’s Izervay Receives FDA Approval for Geographic Atrophy Treatment
Japan-based Astellas Pharma Inc., (TYO: 4503) has announced that it has received new market approval...
Ascentage Pharma’s Lisaftoclax (APG-2575) Gets FDA Green Light for Phase III Study
China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the US...
Grand Pharmaceutical Group Gets NMPA Approval for Generic Eplerenone for Hypertension
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...
CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...
ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma
Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from...
Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials
Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have...
Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance
Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...
Abbisko Therapeutics Initiates Phase II Clinical Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the dosing of the first...
Astellas Pharma’s Zolbetuximab BLA Accepted by China’s CDE for Gastric Cancer Treatment
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that the Center for Drug Evaluation (CDE)...
GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer
GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...
Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna
US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA)...
RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...
Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...
Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment
China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...
Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...
Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China
China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...
Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density
China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...
Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...